Delivery Order SPE2DB20D9127-SPE2DB23FPRJ8
- Not listed
- This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $78,899.37 contract is for the delivery of 3,750 units of the drug Asparlas (5 ml vial) with a completion date of November 30, 2023. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a wide...
- This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA). The $148,084.30 contract is for the delivery of 3,750 units of the pharmaceutical product ASPARLAS (5 ML vial) with a completion date of July 29, 2025. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler that specializes in providing a range of medical products to federal agencies, including the DLA. The company holds a significant...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $27,614.78, is for the delivery of 3,750 units of the drug ASPARLAS (5 mL vials) with a completion date of May 17, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business. The order is for 3,750 units of the pharmaceutical product ASPARLAS (5 ml vials) with a potential value of $124,714.50 and a completion date of January 30, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that provides a range of brand-name and generic prescription and over-the-counter drug supplies to the federal...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $27,614.78 contract is to provide 3,750 units of the pharmaceutical product ASPARLAS (5 mL vials) with an ultimate completion date of April 10, 2024. DMS Pharmaceutical Group holds a $4,999,999 indefinite delivery vehicle (IDV) contract with DLA under the SPE2DB program to supply a broad range of pharmaceutical...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $138,073.90, is for the delivery of 3,750 units of the pharmaceutical product ASPARLAS in 5 ML vials. The contract has no set-aside designation and is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA. This IDC,...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 3,750 units of the pharmaceutical product ASPARLAS in 5 ml vials. The contract has a firm-fixed price of $148,084.30 and a period of performance ending on June 26, 2025. DMS Pharmaceutical Group Inc. has a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $59,233.74 by the Defense Logistics Agency on September 10, 2025. The delivery order, with an ultimate completion date of October 1, 2025, calls for the supply of 3,750 units of Asparlas in 5 milliliter vials. This award was issued without a set-aside designation and represents a specific product delivery under DMS...
- This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) under the SPE2DB program. The award, valued at $55,229.58, is for the delivery of 3,750 units of the pharmaceutical product ASPARLAS (5 mL vial). This order is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $82,844.34, is for the delivery of 3,750 units of the 5 ML vial pharmaceutical product ASPARLAS, with a completion date of December 30, 2024. DMS Pharmaceutical Group holds a larger single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
- SPE2DB20D9127Indefinite Delivery Contract
- SPE2DB20D9127-SPE2DB23FPRJ8Delivery Order
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $52,599.60, is for the delivery of 3,750 units of the pharmaceutical product Asparlas (5 ml vial) by September 14, 2023. DMS Pharmaceutical Group holds a large Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC allows the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The current delivery order is not associated with any set-aside designation, leveraging DMS Pharmaceutical Group's status as a woman-owned small business to secure this direct federal award.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $52.6k | 8/23/23 |